Melanocortin receptor agonist (FDA-approved: Vyleesi)
A synthetic cyclic peptide that increases sexual desire/arousal by acting on the brain rather than blood flow.
| Class / type | Melanocortin receptor agonist (FDA-approved: Vyleesi) |
|---|---|
| Category | Sexual, Skin & Aesthetic |
| Status (Jul 2026) | FDA-approved |
PT-141 (bremelanotide) is a melanocortin-receptor agonist that increases sexual desire by acting on the brain rather than on blood flow. It is FDA-approved as Vyleesi for acquired, generalized hypoactive sexual desire disorder (HSDD) in premenopausal women.
It is widely used off-label for libido and arousal in men and other groups; those uses are not FDA-approved. Research-grade PT-141 sold in vials is not the approved product.
PT-141 activates central melanocortin receptors (mainly MC4R) in the brain. This is a fundamentally different pathway from PDE5 inhibitors like Viagra or Cialis, which work on blood vessels - PT-141 targets desire itself, upstream of the physical response.
Bremelanotide has Phase 3 trial evidence for HSDD in premenopausal women, which is the basis for its FDA approval as Vyleesi. Its off-label uses (men, postmenopausal women) are supported mostly by smaller studies and anecdote rather than pivotal trials.
Boosts genuine desire rather than just mechanical function, works independently of the vascular system, and can be dosed on-demand (about 45 minutes before activity). Many users report it works for both men and women.
It is the only fully FDA-approved compound among the community-popular 'sexual wellness' peptides.
Nausea is very common (around 40% in trials); flushing, headache and injection-site reactions also occur.
It transiently raises blood pressure and lowers heart rate, so it is contraindicated in uncontrolled hypertension or known cardiovascular disease. Focal hyperpigmentation (darkening of skin, gums or face) can occur, more likely with repeated use or in darker skin, and may not fully resolve.
As Vyleesi it is prescription-only and dosed on-demand. Off-label and research-grade use is common but unapproved; the blood-pressure effect makes a cardiovascular check-in worthwhile.
Boosts genuine desire (not just mechanical function), works for men and women; on-demand 'brain-level' arousal.
FDA-approved as Vyleesi (2019) for HSDD in premenopausal women - the only fully FDA-approved compound in this group. Other uses are off-label / research-use-only.